Enter a “Risen Star”: Burcu F. Darst, PhD
Enter a “Risen Star”: Burcu F. Darst, PhD Did you ever wish you could see your genetic future – what awaits you in your life’s road and what could you do to avert a potential danger to your long life…
QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
Read More
Doctors Catalona, Theodorescu, and Svendsen are recruiting research participants for a new study: family studies of BRCA2-related prostate cancer
Prostate cancer is the most common cancer in men. Age, family history of prostate cancer, and germline variation are the most established risk factors, with as much as 57% of the variability in prostate cancer risk estimated to be due…
What are embryonic stem cells and how can they help us?
All living things, including humans, are made of cells. Each tissue and organ of the body contain cells that are specialized to perform specific jobs-the brain contains neurons, the eyes contain light-detecting cells and so on. All human life begins…
Decline in PSA levels is associated with improved survival
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is inceasingly included in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). In this analysis, 184 patients were treated with 177Lu-PSMA RLT. Response to treatment was defined as decrease in PSA…
A more robust follow-up protocol may be necessary for some men
There is no standard follow-up protocol for men with a negative evaluation with systematic biopsies and multiparametric MRI (mpMRI) and a persistent clinical suspicion of prostate cancer. This study assessed the proportion of clinically significant prostate cancers during follow-up after…
Olaparib improves health related quality of life in patients with metastatic castration-resistant prostate cancer.
Treatment with Olaparib was associated with a reduction in pain and improvement in health-related quality of life compared with physician’s choice of hormone therapy (enzalutamide or abiraterone) in patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA-repair deficiency genetic mutations…
Maximum tumor diameter provides information before treatment
Maximum tumor diameter on pretreatment MRI has the potential to provide further information to men with prostate cancer before definitive treatment. This retrospective analysis included a cohort of 631 patients. Analysis identified 4 prognostic groups for patients treated with radical…
Healthy lifestyle cuts prostate cancer mortality among high-risk men
Adherence to a healthy lifestyle is associated with close to a 50% lower risk for developing lethal prostate cancer among men at high risk for the disease according to a recent study. The analysis included 12,411 genotyped men. The researchers…
Efficacy of PSMA-radioguided surgery
In this phase II trial, the authors investigated the efficacy of prostate-specific membrane antigen (PSMA)-radioguided surgery in identifying lymph node invasion during robot-assisted radical prostatectomy in patients with clinically-localized prostate cancer. Overall, 12 patients with intermediate-or high-risk prostate cancer underwent…
Association between PSA screening and prostate cancer mortality among non-Hispanic Black and non-Hispanic White US veterans
Black men have higher prostate cancer incidence and mortality than non-Hispanic white men. However, Black men have been underrepresented in clinical trials of PSA screening; therefore, there is a lack of data to guide screening recommendations for this population. The…
